Introduction {#S1}
============

The postural tachycardia syndrome (PoTS) is characterized by symptoms of orthostatic intolerance and an excessive increase in heart rate (by ≥30 or to ≥120 bpm) when upright ([@B1]--[@B3]). Typical complaints of the otherwise healthy patients are palpitations, weakness, blurred vision, chest pain, sweating, dizziness, presyncope, shortness of breath, tremulousness, fatigue, poor nocturnal sleep, and sleep dysfunction including waking up at night repeatedly and night sweating ([@B4]). PoTS is a heterogeneous and multifactorial disorder ([@B5]). PoTS manifests itself with symptoms of cerebral hypoperfusion and excessive sympathoexcitation but the exact pathophysiology remains as of yet unknown. It has however been found that the pathophysiology of PoTS includes impaired sympathetically mediated vasoconstriction, excessive sympathetic drive, volume dysregulation, and deconditioning, which can all be variously combined.

As mentioned before, some of the chief complaints of PoTS patients are increased daytime sleepiness, fatigue, and diminished quality of night time sleep. In 1921, Swan et al. already mentioned sleep disturbances in relation to PoTS-like symptoms ([@B6]). Also Craig et al. and Wood et al. mentioned the incidence of sleep disturbances in their publications regarding neurocirculatory asthenia, which is consistent with today's definition of PoTS ([@B7], [@B8]). Recent studies confirmed this coherency. In 2007, Thieben et al. investigated 152 medical records which showed that 31.6% of PoTS patients had sleep disturbances and even 48% had severe fatigue ([@B4]). Bagai et al. discovered significantly more severe sleep disturbances, higher fatigue levels, and excessive daytime sleepiness in a group of 44 PoTS patients compared to normal controls (*n* = 46) using questionnaires ([@B9]). All published evidence is focused on the subjective sleep quality of PoTS patients or actigraphy ([@B10]). As of yet, there is no published data regarding objective sleep evaluation of PoTS patients with a polysomnographic (PSG) examination of their sleep quality. The aim of this study is therefore to evaluate subjective and objective sleep quality of PoTS patients compared to a group of healthy controls matched in age and gender. As both sleep and PoTS may be affected by the regulation of the autonomic nervous system (ANS), it can be assumed, that a connection between autonomic dysfunction and sleep disturbance exists. To evaluate this putative coherency, heart rate variability (HRV) was used as an objective measurement for the ANS.

Materials and Methods {#S2}
=====================

The present clinical trial is a prospective competitive study of patients and controls who presented to the Department of Neurology and Neurophysiology, Helios Klinikum Wuppertal in between June 2010 and September 2011. PoTS patients were mainly examined during the course of their hospitalization. Control subjects were recruited within private contacts and examinations were performed as outpatients. Within the study, we examined 38 patients, which fulfilled conventional criteria of PoTS and 31 healthy control subjects that did not show any symptoms of orthostatic intolerance. All participants completed an informed consent form prior to taking part. Inclusion criteria for the PoTS group were symptoms of orthostatic intolerance plus an increase in heart rate by ≥30 or to ≥120 bpm during upright position. Excluding criteria for both patient groups were all conditions that could affect the autonomous nervous system, such as Parkinson's disease, diabetes mellitus, alcoholism, hypertension, defects of the thyroid, pheochromocytoma, anemia, dementia, multiple sclerosis, cardiac arrhythmias, or polyneuropathy. Furthermore, patients with psychiatric disorders were excluded. A constant medication or current pregnancy was additional exclusion criterion.

Autonomic testing {#S2-1}
-----------------

All participants underwent a 70°-tilt table study at the Autonomic Laboratory at Helios Klinikum Wuppertal in order to assess their orthostatic cardiovascular function. All subjects were examined between 7.30 a.m. and 12.30 a.m. Time spent upright on the tilt table varied between 10 and 45 min, depending on the patients tolerance. During this procedure, blood pressure, heart rate, and breathing rate were continuously monitored by a FAN™ computer (Schwarzer, Heilbronn, Germany). Blood pressure was additionally continuously measured with a Portapress device (TNO-TPD Biomedical Instrumentation, Amsterdam, Netherlands) following the method described by Penáz ([@B11], [@B12]). Each participant completed a Valsalva maneuver during which blood pressure and heart rate were monitored. The maneuver was accomplished in supine position ([@B13]). After a rest period of 1 min, each participant was asked to expirate against a pressure of 20--40 mmHg for approximately 15 s. Valsalva ratio and changes of blood pressure were measured by the FAN™ device (Schwarzer GmbH, Munich, Germany). The FAN™ device records HRV based on the standard recording techniques and algorithms used in autonomic function studies ([@B14]). The FAN™ has an interface box for the recording of ECG, breathing frequency, and expiratory pressure, e.g., during Valsalva maneuver. ECG and breathing frequency were digitized with a sampling rate of 500 Hz; where the expiratory pressure could be recorded with the limits of 0--100 mm mercury. The interface also offers the opportunity to record one analog external signal of blood pressure from an external monitor (digitizing rate 500 Hz).

Polysomnography {#S2-2}
---------------

All participants were monitored in the Sleep Unit, Helios Klinikum Wuppertal that fulfills the requirements by the German Society of Sleep Science and Sleep Medicine (DGSM). As a standard procedure, all patients stayed overnight and were attended with PSG. The recordings were evaluated using "Alice 5" -- PSG soft -- and hardware (Heinen & Loewenstein, Bad Ems, Germany). The PSG recording included six channel electroencephalogram (EEG) (including frontal, central, occipital bilateral referencing to right and left mastoid), right and left electro-oculography, bilateral surface EMG of mentalis and of right and left tibialis anterior muscles, 2 channel ECG, oronasal thermistor, thoracic and abdominal respirograms, absolute position transducer larynx microphone, and oxygen saturation. The subjects reported to the sleep unit at 8.00 p.m. Monitoring was performed for at least 6 h (10 p.m. until 5 a.m.) All patients were monitored over the period of one night.

Data analysis {#S2-3}
-------------

Sleep data were staged visually according to the rules of Rechtschaffen & Kales and furthermore according to the criteria of the American Association of Sleep Medicine using 30 s time frames, by two independent investigators ([@B15], [@B16]). PSG parameters like mean heart rate in NREM and REM sleep, Total sleep time (TST), total in bed time (TIBT), sleep efficiency (TST/TIBT), sleep onset latency (minutes), REM latency (minutes), quantity of stage 2 (%), slow wave sleep (%), and REM (%) sleep were analyzed. Arousals were defined as abrupt changes in EEG pattern with return to alpha or theta frequency, lasting between 3 and 10 s and were also analyzed according to the criteria of the American Association of Sleep Medicine ([@B16]).

Heart rate variability {#S2-4}
----------------------

Heart rate variability data were detected using ECG signals: 5 min segments of artifact-free ECG data during sleep stage 2, slow wave sleep, and REM sleep were selected for analyses ([@B17]). ECG lines were extracted from Alice 5 software and transferred to the *fan* computer by an ASCI file. All ECG lines were visually controlled for artifacts and extra-systoles. HRV was automatically analyzed with ASCI 2 at a sampling rate of 500 Hz by the Fan device software according to the "Recommendations of the International Federation of Clinical Physiology for the Practice of Clinical Neurophysiology" ([@B18], [@B19]). In short, the ECG signal was digitized at a sample rate of 500/s. Respiration was monitored by registration of chest movements. A fast Fourier transform (FFT)-based algorithm was used for the spectral analysis of HRV. The RR intervals were converted to 4 Hz and an exact Hamming window was applied for FFT. The power in frequency ranged from low frequencies (LF: 0.04--0.15 Hz) to high frequencies (HF: 0.15--0.40 Hz). Spectral analysis allowed a differentiation of sympathetic and parasympathetic activation, which were related to a LF and a HF component of the HRV signal, respectively. LF band reflected a combination of sympathetic and parasympathetic influences and baroreflex function. HF band reflected parasympathetic activity. The resulting LF/HF ratio as a quantitative index of the sympathovagal balance was calculated.

Epworth Sleepiness Scale {#S2-5}
------------------------

The Epworth Sleepiness Scale (ESS) is a standardized questionnaire, which documents subjective daytime sleepiness. It is focused on eight specific daily situations including sitting, reading, watching television, passive sitting (e.g., in a theater), co-driving, while stopping and driving (e.g., on a traffic light), afternoon rest, sitting while having a conversation and after lunch (without the consumption of alcohol). Patients were asked to rank sleepiness in these situations on a scale of 0--3 points. Total possible maximum would have been 24 points. Prior studies showed that an ESS Score over 10 is related to enhanced daytime sleepiness ([@B20]).

Pittsburgh Sleep Quality Index {#S2-6}
------------------------------

The Pittsburgh Sleep Quality Index (PSQI) is a standardized questionnaire to retrospectively document subjective sleep quality during the past for weeks ([@B21]). Its seven categories consist of subjective sleep quality, sleeping time, sleep latency, intake of sleep medication, sleep efficiency, sleep disturbances, and daytime sleepiness. Each category can score up to three points. Total maximum score would be 21 points. Participants could be classified in three groups. A score of ≤5 indicates good quality of sleep, a score ≥5 and ≤10 indicated minor quality of sleep, and a score of ≥10 correlated with chronic sleeping disorders.

Ethics of investigations {#S2-7}
------------------------

All clinical studies conformed with the principals of the declaration of Helsinki. A positive voting of the Ethics committee of the University of Witten/Herdecke had been obtained prior to data collection.

Statistical methods {#S2-8}
-------------------

All statistical analyses were performed using SPSS for Windows v. 20.0 (SPSS Inc., Chicago, IL, USA) with assistance of the statistician Dr. Lange. Descriptive statistics are presented as mean ± SD or median \[plus interquartile range (\>IQR)\]. To compare independent variables Mann--Whitney-*U* or Fisher Tests were performed. For more than two dependant variables, Friedman test was used. All tests were two-tailed. Statistical significance was set at *p* = 0.05.

Results {#S3}
=======

Demographics {#S3-9}
------------

Sixty-nine persons in total were examined, 38 patients with PoTS, and 31 healthy controls. PoTS patients were predominantly female (74%). They were between 18 and 41 years of age, with a mean age of 25.3 ± 7 years (females: 24.4 ± 6.2 years, males: 27.8 ± 8.1 years). Age and gender of control subjects was adapted to the PoTS group not resulting in significant differences (age *p* = 0.183, gender *p* = 0.518). Thirty-one healthy participants were assigned to the control group, 20 females (65%) and 11 males. The mean age of this group was 26.2 ± 6.3 years (females: 25.7 ± 5.8 years, males: 27.2 ± 7.5 years). Controls were recruited within a university setting.

Autonomic testing {#S3-10}
-----------------

Head-up tilt table testing showed an increase in heart rate of PoTS patients with a median of 38.99 bpm (30.00--43.00). This was significantly higher than in controls (*p* = 0.000), who showed a median in heart rate increase by 15.00 bpm (12.00--25.00). No significant changes in blood pressure were found in both groups. During Valsalva maneuver, blood pressure was continuously measured. PoTS patients had an increase in systolic blood pressure during phase 4 of the maneuver with a median of 27.00 (16.00--44.00) mmHg. Controls, however, showed an increase systolic pressure with a median of 21.00 (15.00--26.00) mmHg, resulting in a statistically significant difference in between groups (*p* = 0.019). PoTS patients showed furthermore significantly higher parameters in the Valsalva ratio (1.92 vs. 1.75; *p* = 0.0036).

Subjective sleep quality and sleepiness {#S3-11}
---------------------------------------

Twenty-five PoTS patients and 31 control subjects answered PSQI and ESS questionnaires. The maximum PSQI score reached by PoTS patients was 17, controls reached a maximum score of 12. Ten PoTS patients accomplished a score ≥10 (40%). Whereas only one participant of the control group scored ≥10. Compared to controls, PoTS patients reached a significantly higher score in PSQI \[PoTS in median: 8 (4--13); where controls had a median of 4 (3--5) *p* = 0.01\]. PoTS patients reach higher scores in ESS than controls, but the median did not exceed the cut-off of 10 \[PoTS in median: 6 (3--9); where Controls had a median of 3 (1--5) *p* = 0.01\]. The maximum score in the PoTS group was 17, participants in the control group reached a maximum score of 7. 24% of PoTS patients reached a score over 10, while none of the control subjects did, however, this did not reach statistic significance (*p* = 0.088).

Polysomnography {#S3-12}
---------------

The mean heart rate during different sleep stages is shown in Table [1](#T1){ref-type="table"}. PoTS patients have a higher mean heart rate in both sleep stages, NREM and REM, but there is no significant difference between the two groups (Table [1](#T1){ref-type="table"}). Parameters that describe the sleep efficiency did not differ significantly in both groups (Table [2](#T2){ref-type="table"}). Both groups slept well, with a total sleeping time in median of 359.00 (324.50--381.50) minutes (PoTS) and 350.00 (332.50--375.50) minutes (controls) and sleep efficiencies in median of 96.03 (91.54--98.46)% (PoTS) and 95.56 (93.06--98.38)% (controls). PoTS patients have a significantly higher percentage of stage 2 sleep than controls (42.45 vs. 36.70%; *p* = 0.017). They also show a slightly lower proportion of slow wave sleep (39.25 vs. 41.30%). PoTS patients show a higher proportion of REM sleep (15.10 vs. 12.90%). Furthermore, four of the PoTS patients did not even reach REM sleep stage during the whole night.

###### 

**Heart rate during NREM and REM sleep presented in median with its interquartile range**.

  Variable               PoTS                     Controls                 *p* Value
  ---------------------- ------------------------ ------------------------ -----------
  Mean heart rate NREM   61.60 (56.10 -- 68.00)   59.60 (54.90 -- 68.90)   0.859
  Mean heart rate REM    66.75 (57.50 -- 70.20)   63.20 (58.50 -- 70.30)   0.864

###### 

**Parameters of sleep efficiency and sleep architecture presented in median with its interquartile range**.

  Variable                             PoTS                        Controls                    *p* Value
  ------------------------------------ --------------------------- --------------------------- -----------
  Total in bed time (TIBT) (minutes)   401.50 (385.00 -- 423.00)   402.00 (386.00 -- 423.00)   0.777
  Sleep period time (SPT) (minutes)    372.00 (349.50 -- 398.50)   368.50 (353.50 -- 396.00)   0.847
  Total sleep time (TST) (minutes)     359.00 (324.50 -- 381.50)   350.00 (332.50 -- 375.50)   0.828
  Sleep efficiency (TST/SPT) (%)       96.03 (91.54 -- 98.46)      95.56 (93.06 -- 98.38)      0.981
  TST/TIBT (%)                         90.52 (82.95 -- 93.78)      87.26 (84.54 -- 91.72)      0.546
  Sleep latency (minutes)              21.25 (16.50 -- 29.00)      24.50 (17.00 -- 38.00)      0.393
  REM latency (minutes)                138.50 (64.00 -- 192.50)    122.50 (84.50 -- 227.50)    0.173
  Sleep stage 2 (%)                    42.45 (35.30 -- 48.60)      36.70 (30.60 -- 43.00)      0.017
  Slow wave sleep (%)                  39.25 (31.40 -- 47.90)      41.30 (33.00 -- 50.90)      0.337
  REM (%)                              15.10 (6.90 -- 19.80)       12.90 (9.90 -- 18.70)       0.537

Arousals {#S3-13}
--------

Arousals during night time sleep was measured and manually assessed. It was defined as an increase in EEG frequency lasting at least over a period of 3--10 s. In PoTS patients, there was a total of 41.00 (33.00--50.00) arousals measured, while control subjects showed only 37.00 (27.00--66.00; n.s.). Three of the PoTS patients showed 15 or more periodic leg movements (PLM) per hour, which is consistent with nocturnal movement disorder. One of the PoTS patients showed an index as severe as 54/h. None of the control subjects exhibited more than 11 PLM/h. Furthermore, one of the PoTS patients was diagnosed with obstructive sleep apnea with a REM-AHI of 41.5/h and AHI 10.5/h, showing a mean of nine respiratory arousals per hour. In control subjects, no respiratory arousals could be identified.

Heart rate variability {#S3-14}
----------------------

### Low-frequency band {#S3-14-1}

No significant difference in the LF band component between the two groups was found (Table [3](#T3){ref-type="table"}). There is no significant increase or decrease of the LF band during different sleep stages in PoTS patients, whereas individuals in the control group had a significant decrease in sleep stage 2 to slow wave sleep (*p* = 0.014). In a summary, these results showed a reduction of variability of the LF band during different sleep stages in PoTS patients.

###### 

**LF band power (ms^2^/s.) across different sleep stages in median with its interquartile range**.

  Variables         PoTS                        Controls                    *p* Value
  ----------------- --------------------------- --------------------------- -----------
  Sleep stage 2     336.68 (149.52 -- 641.58)   498.09 (185.81 -- 689.04)   0.392
  Slow wave sleep   224.69 (118.87 -- 589.83)   227.18 (89.03 -- 663.87)    0.968
  REM               365.20 (155.00 -- 591.14)   285.77 (165.65 -- 562.34)   0.767

### High-frequency band {#S3-14-2}

There was no statistically significant difference between HF bands in between PoTS patients and controls (Table [4](#T4){ref-type="table"}). In controls, there were significant differences of HF band between stage 2 and slow wave sleep (*p* = 0.018) and stage 2 and REM (*p* = 0.006), but there was no statistical difference between HF band of slow wave sleep and REM. In PoTS patients, there was no statistical difference of HF band increase or decrease between sleep stages 2, slow wave sleep, and REM. HF band of PoTS patients did not vary in between sleep stages as much as control subjects.

###### 

**HF band power (ms^2^/s) across different sleep stages in median with its interquartile range**.

  Variables         PoTS                        Controls                    *p* Value
  ----------------- --------------------------- --------------------------- -----------
  Sleep stage 2     333.10 (188.72 -- 600.79)   250.91 (155.79 -- 969.79)   0.975
  Slow wave sleep   342.34 (181.68 -- 621.52)   237.18 (166.18 -- 678.45)   0.386
  REM               227.39 (112.47 -- 749.35)   176.39 (62.62 -- 389.17)    0.192

LF/HF ratio {#S3-15}
-----------

There was no statistically significant difference between the two study groups (Table [5](#T5){ref-type="table"}). PoTS patients showed a decrease of LF/HF ratio from stage 2 to stage 4 (n.s.) and an increase to stage REM (n.s.). In controls, there were significant changes in HRV in between sleep stages. LF/HF ratio was higher in sleep stage 2 than in slow wave sleep (*p* = 0.265), and in both stage 2 (*p* = 0.002) and slow wave sleep (*p* = 0.002) were significantly lower compared to REM sleep. PoTS patients show a reduction of LF/HF ratio variability in different sleep stages.

###### 

**LF/HF ratio across different sleep stages in median with its interquartile range**.

  Variables         PoTS                  Controls              *p* Value
  ----------------- --------------------- --------------------- -----------
  Sleep stage 2     0.82 (0.47 -- 1.69)   0.93 (0.58 -- 1.99)   0.542
  Slow wave sleep   0.64 (0.36 -- 1.41)   0.81 (0.46 -- 2.21)   0.386
  REM               1.14 (0.51 -- 2.63)   1.52 (0.87 -- 3.91)   0.187

Discussion {#S4}
==========

In order to assess subjective and objective sleep quality of PoTS patients, this study considered a group of 38 PoTS patients and compared them to a group of 31 healthy controls matched in age and gender. All patients included met standard diagnostic criteria for PoTS. Basically, the results obtained in this study confirmed current literature, i.e., PoTS patients showed physiological autonomic control of the baroreflex arc as shown by the Valsalva maneuver with diminished subjective sleep quality and increased daytime sleepiness. For the first time, it was demonstrated that in PoTS patient the macrostructure of sleep is physiological by means of PSG recording. Autonomic testing showed a significantly higher Valsalva ratio in PoTS patients as compared to normal subjects. This conforms to former studies of Sandroni et al. who found a higher Valsalva ratio in PoTS patients and ascribed this to an increased β-adrenergic tone ([@B22]). Furthermore, there was a higher increase in systolic blood pressure in PoTS patients during Valsalva maneuver compared to control subjects, which also reflected the findings of Sandroni et al. ([@B22]). Forty percent of PoTS patients in this study suffered from subjective diminished sleep quality as evaluated by a standardized PSQI questionnaire. Furthermore, 24% reached an ESS score above 10, which reflected excessive daytime sleepiness in those patients. Our study confirmed the results of Thieben et al., who reported that 31.6% of a cohort of 152 PoTS patients suffered from sleep disturbances and even 48.0% that complained about fatigue ([@B4]). Bagai et al. reported 51% PoTS patients (*n* = 44) with excessive daytime sleepiness ([@B9]). One could expect a coherency of diminished subjective sleep quality, increased daytime sleepiness, and diminished sleep efficiency. In our study, PSG parameters showed no differences in sleep efficiency or frequency of arousals between both groups. One of the PoTS patients was diagnosed with sleep apnea and treated with CPAP (ESS score 2) whilst two PoTS patients showed increased PLM during night, these patients also showed ESS scores over 10, which could be due to PLMs. The significance of these findings needs further evaluation. However, sleep architecture showed a significantly higher proportion of sleep stage 2 in patients with PoTS. This phenomenon could also be detected in patients with insomnia and points out the evidence of objective primary sleep disorders in PoTS patients. Slow wave sleep percentage was slightly higher in control subjects (39.25 vs. 41.30%; n.s.), but not statistically significant. There was no significant difference in the proportion of REM sleep between the two groups. However, four of the PoTS patients did not even reach REM sleep stage throughout the night.

Spectral analyses of HRV data during different sleep stages (sleep stage 2, slow wave sleep, and REM) demonstrated characteristic sleep stage-related changes in ANS activity in control subjects ([@B23]--[@B27]). Parasympathetic activity increased with synchronization of sleep while LF/HF ratio which presents sympathovagal balance decreased. In REM sleep, LF/HF ratio increased, which indicates a sympathetic dominance. Separate analyses of LF band, HF band, and LF/HF ratio showed stage-related differences between the two patient groups. In control subjects, LF band showed a significant decrease from sleep stage 2 to slow wave sleep, which could not be detected in patients with PoTS. Furthermore in control subjects, HF band showed a significant decrease from sleep stage 2 to slow wave sleep and also from slow wave sleep to REM sleep. In PoTS patients, HF band did not vary to the same extent. Median values of the LF/HF ratio appeared to be consistently lower in PoTS patients. With reference to LF/HF ratio, there was a significant increase from sleep stage 2 to REM sleep and also from slow wave sleep to REM sleep in control subjects. In PoTS patients, no significant stage-related change in LF/HF ratio was seen. This phenomenon leads to the conclusion that PoTS patients have an altered HRV during night. In some PoTS patients, cardiac dysautonomic neuropathy with reduced myocardial 123I-meta-iodobenzylguanidine uptake was reported, which could also be a reason for diminished HRV in different sleep stages ([@B28], [@B29]). An altered state dependent modulation of HRV may not only derive from cardiac dysautonomic neuropathy, but also from a hyperadrenergic state ([@B5]).

As a limitation of the present study, the results of sleep efficiency, sleep architecture, and arousal frequency should be interpreted carefully since they could be affected by a "first night effect" ([@B30]) due to the lack of an adaption night. However, according to Israel et al., HRV is not affected by the "first night effect" ([@B31]). With regard to the measurement of arousals, the present study is limited by the consideration of changes in EEG patterns only. If there are other sorts of arousals, which would only affect cardiorespiratory parameters, like autonomic arousals presumably do, they would have not been evaluated by the present trial. In fact, there is no proper definition to classify autonomic arousals to this date. Future studies into this field could evaluate autonomic arousal, since it may affect sleep architecture and cause sleep disturbances in PoTS patients. Very recently Sasai et al. found that an elevation of sympathetic nervous system activity and mean frequency fluctuation in an HF band can occur several seconds before the period of PLMs. Therefore, specific analysis of HRV in PLM period could be an interesting aspect for future research. Our results are probably unaffected by autonomic fluctuation prior to PLMs, since analyzed HRV periods were copied to the ECG at least 10 min before or after an arousal occurred. The presence of PLMS or OSA(S) (AHI 10.5/h) may be a confounding factor for analysis. Another theory, which is not evaluated in the present study, is the coherency of sleep difficulties and anxiety in PoTS patients. It is conceivable that this could be an alternative cause of sleeping disorders, as a connection between anxiety disorders and sleep disturbances in other patients as already reported by Soehner et al. ([@B32]). On the other hand, in a previous study, it has been found that an increase of propensity to anxiety disorders existed in PoTS only when questionnaires were used that included autonomic items ([@B33]). For further research, PoTS patients could be divided into two groups via PSQI and ESS scores, thus autonomic parameters in PoTS patients could be compared with and without subjective sleeping disorder/sleepiness. From a statistical point of view, a large number of variables were tested without controlling for type I error (e.g., Bonferroni approach). The study is also restricted by performing it only in the Helios Klinikum Wuppertal and results may not be transmitted to other settings due to, e.g., other ethnicities in other clinical setting.

Conclusion {#S5}
==========

Postural tachycardia syndrome patients had a subjective diminished sleep quality, reached higher levels of daytime sleepiness, and showed a diminished proportion of sleep stage 2. Since all these symptoms can be also seen in patients with insomnia, PoTS should be included as a potential differential diagnosis of insomniacs. PoTS patients showed normal sleep when objectively evaluated by PSG. Furthermore, analyses of HRV during different sleep stages showed altered HRV during different sleep stages in PoTS. Sleep physicians should be aware of sleep disturbances associated with this form of orthostatic intolerance.
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